Cipaglucosidase Alfa: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Cipaglucosidase Alfa. Educational only — not medical advice.

Labeled uses

POMBILITI is indicated, in combination with Opfolda, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT).

Source: FDA labeling via NIH DailyMed (set d77aa596…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.

Ratings summarize government-reported measures — they don't capture your personal needs. Visit the facility, ask about staffing and services, and use CMS checklists. This profile is informational only and is not a recommendation.